Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous Immunotherapy With Multi-target Gene-modified CAR-T/TCR-T Cell for Malignancies

NCT03638206 is registered in ClinicalTrials.gov with Shenzhen BinDeBio Ltd. as lead sponsor.

NCT NCT03638206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03638206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous Immunotherapy With Multi-target Gene-modified CAR-T/TCR-T Cell for Malignancies
Lead sponsor
Shenzhen BinDeBio Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 1, 2018
Completion date
March 1, 2023
Enrollment
73 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia, colorectal cancer, esophagus cancer, gastric cancer, glioma, hepatoma, lung cancer, lymphoma, melanoma, mesothelioma, multiple myeloma, myeloid leukemia, ovarian cancer, pancreatic cancer, renal carcinoma, synovial sarcoma